Mesenchymal stromal cells for acute graft-versus-host disease: response at 1 week predicts probability of survival.
Authors
Galleu, AMilojkovic, D
Deplano, S
Szydlo, R
Loaiza, S
Wynn, R
Marks, D
Richardson, D
Orchard, K
Kanfer, E
Tholouli, E
Saif, M
Sivaprakasam, P
Lawson, S
Bloor, Adrian
Pagliuca, A
Potter, V
Mehra, V
Snowden, J
Vora, A
Kishore, B
Hunter, H
Apperley, J
Dazzi, F
Affiliation
King's College London, London, UKIssue Date
2019
Metadata
Show full item recordAbstract
Mesenchymal stromal cells (MSCs) have been successfully used for the treatment of steroid-resistant graft-versus-host-disease (GvHD). However, the lack of early predictors of clinical responses impacts on the time at which to add further treatment and consequently the design of informative clinical trials. Here, we present the UK experience of one of the largest cohorts of GvHD patients undergoing MSC infusions so far reported. We show that clinical responses assessed as early as 1 week after MSC infusion predict patients' overall survival. In our cohort, cell dose, patients' age and type of organ involvement are crucial factors associated with clinical responses.Citation
Galleu A, Milojkovic D, Deplano S, Szydlo R, Loaiza S, Wynn R, et al. Mesenchymal stromal cells for acute graft-versus-host disease: response at 1 week predicts probability of survival. Br J Haematol. 2019 Jan 13.Journal
British Journal of HaematologyDOI
10.1111/bjh.15749PubMed ID
30637732Additional Links
https://dx.doi.org/10.1111/bjh.15749Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1111/bjh.15749